EP300 and breast cancer: The fact that at least some of them were previously confirmed to be enriched in BRG1–EP300 functional complexes [12] prompted us to check if EP300 interacted with PARP1 and if any of BRG1–EP300 components could undergo ADP-ribosylation in proliferating breast cancer cells.